Literature DB >> 29120691

Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL): Overview and introduction to the proceedings of the 2016 TACL investigator meeting.

Alan S Wayne1, Erika Shin-Kashiyama1, Richard Sposto1, Paul Gaynon1.   

Abstract

Despite great success in the development of curative therapies for pediatric hematologic malignancies, new approaches are needed to overcome resistance to treatment and to reduce associated side effects. The Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium is an early phase clinical trial group dedicated to developing innovative therapies for currently incurable pediatric leukemias and lymphomas ( https://tacl.chla.usc.edu/tacl/ ). In November of 2016, a TACL Investigator Meeting was held, the proceedings of which appear in this edition of Pediatric Hematology Oncology. This introductory article provides an overview of TACL and introduces the five-part proceedings.

Entities:  

Keywords:  Clinical trials; leukemia; lymphoma; molecularly targeted agents; pediatric

Mesh：

Year:  2017        PMID： 29120691      PMCID： PMC6122960          DOI： 10.1080/08880018.2017.1377329

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN： 0888-0018            Impact factor:   1.969


  14 in total

1.  Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) study group.

Authors:  Bettina Reismüller; Christina Peters; Michael N Dworzak; Ulrike Pötschger; Christian Urban; Bernhard Meister; Klaus Schmitt; Karin Dieckmann; Helmut Gadner; Andishe Attarbaschi; Georg Mann
Journal:  J Pediatr Hematol Oncol       Date:  2013-07       Impact factor: 1.289

2.  A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.

Authors:  Todd M Cooper; Jeannette Cassar; Elena Eckroth; Jemily Malvar; Richard Sposto; Paul Gaynon; Bill H Chang; Lia Gore; Keith August; Jessica A Pollard; Steven G DuBois; Lewis B Silverman; Javier Oesterheld; Guy Gammon; Daniel Magoon; Colleen Annesley; Patrick A Brown
Journal:  Clin Cancer Res       Date:  2016-02-26       Impact factor: 12.531

3.  Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study.

Authors:  Matthew F Gorman; Lingyun Ji; Richard H Ko; Phillip Barnette; Bruce Bostrom; Raymond Hutchinson; Elizabeth Raetz; Nita L Seibel; Clare J Twist; Elena Eckroth; Richard Sposto; Paul S Gaynon; Mignon L Loh
Journal:  Pediatr Blood Cancer       Date:  2010-09       Impact factor: 3.167

4.  Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.

Authors:  Stephen P Hunger; Xiaomin Lu; Meenakshi Devidas; Bruce M Camitta; Paul S Gaynon; Naomi J Winick; Gregory H Reaman; William L Carroll
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

Review 5.  Childhood acute lymphoblastic leukaemia and relapse.

Authors:  Paul S Gaynon
Journal:  Br J Haematol       Date:  2005-12       Impact factor: 6.998

6.  Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.

Authors:  Terzah M Horton; Richard Sposto; Patrick Brown; C Patrick Reynolds; Stephen P Hunger; Naomi J Winick; Elizabeth A Raetz; William L Carroll; Robert J Arceci; Michael J Borowitz; Paul S Gaynon; Lia Gore; Sima Jeha; Barry J Maurer; Stuart E Siegel; Andrea Biondi; Pamela R Kearns; Aru Narendran; Lewis B Silverman; Malcolm A Smith; C Michel Zwaan; James A Whitlock
Journal:  Pediatr Blood Cancer       Date:  2010-07-01       Impact factor: 3.167

7.  Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.

Authors:  Richard H Ko; Lingyun Ji; Phillip Barnette; Bruce Bostrom; Raymond Hutchinson; Elizabeth Raetz; Nita L Seibel; Clare J Twist; Elena Eckroth; Richard Sposto; Paul S Gaynon; Mignon L Loh
Journal:  J Clin Oncol       Date:  2009-10-19       Impact factor: 44.544

8.  A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.

Authors:  Elizabeth A Raetz; Debra Morrison; Eleny Romanos-Sirakis; Paul Gaynon; Richard Sposto; Deepa Bhojwani; Bruce C Bostrom; Patrick Brown; Elena Eckroth; Jeannette Cassar; Jemily Malvar; Aby Buchbinder; William L Carroll
Journal:  J Pediatr Hematol Oncol       Date:  2014-08       Impact factor: 1.289

9.  Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.

Authors:  Yoav Messinger; Paul Gaynon; Elizabeth Raetz; Raymond Hutchinson; Steven Dubois; Julia Glade-Bender; Richard Sposto; Jeannette van der Giessen; Elena Eckroth; Bruce C Bostrom
Journal:  Pediatr Blood Cancer       Date:  2010-08       Impact factor: 3.167

10.  Chronic health conditions in adult survivors of childhood cancer.

Authors:  Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Toana Kawashima; Melissa M Hudson; Anna T Meadows; Debra L Friedman; Neyssa Marina; Wendy Hobbie; Nina S Kadan-Lottick; Cindy L Schwartz; Wendy Leisenring; Leslie L Robison
Journal:  N Engl J Med       Date:  2006-10-12       Impact factor: 176.079
View more
  3 in total

Review 1.  Immune function in childhood cancer survivors: a Children's Oncology Group review.

Authors:  Gregory M T Guilcher; Linda Rivard; Jennifer T Huang; Nicola A M Wright; Lynette Anderson; Hesham Eissa; Wendy Pelletier; Shanti Ramachandran; Tal Schechter; Ami J Shah; Ken Wong; Eric J Chow
Journal:  Lancet Child Adolesc Health       Date:  2021-02-16

2.  Effect of CB2 Stimulation on Gene Expression in Pediatric B-Acute Lymphoblastic Leukemia: New Possible Targets.

Authors:  Francesca Punzo; Maura Argenziano; Chiara Tortora; Alessandra Di Paola; Margherita Mutarelli; Elvira Pota; Martina Di Martino; Daniela Di Pinto; Maria Maddalena Marrapodi; Domenico Roberti; Francesca Rossi
Journal:  Int J Mol Sci       Date:  2022-08-03       Impact factor: 6.208

3.  Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia: A protocol for systematic review and meta-analysis.

Authors:  Liang Chen; Huai-Xiu Yan; Xiao-Wei Liu; Wen-Xin Chen
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.817
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.